On January 20, 2026, Amanda Crawford, the Chief Financial Officer of Owlet, Inc. (NASDAQ: OWLT), sold 183 shares of the company's common stock at a price of $13.33 per share. This sale yielded proceeds of approximately $2,439 and was carried out to satisfy tax and fee obligations related to the vesting and settlement of restricted stock units, as outlined in a recent Form 4 filing with the Securities and Exchange Commission.
Post-transaction, Crawford retains direct ownership of 150,325 Owlet shares. The company's shares currently trade close to the sale price, around $13.28, and have shown impressive appreciation, delivering a 197% return over the last year — ranking Owlet among top-performing stocks within the market according to InvestingPro data.
Owlet's market capitalization stands near $364 million. Investor consensus, as indicated by analyst price targets, spans a range from $14 to $20 per share. However, InvestingPro models raise caution, suggesting the stock might be overvalued at its current pricing. Market participants look ahead to Owlet's forthcoming quarterly earnings release scheduled for March 11, 2026, which is expected to shed further light on the company's financial course.
In strategic developments, Owlet recently formed a collaboration with 1 Natural Way, a nationwide durable medical equipment supplier. This partnership makes Owlet's FDA-cleared BabySat infant pulse oximeter more accessible to consumers by enabling insurance coverage through commercial plans, state Medicaid programs, and the military-affiliated TRICARE system.
Moreover, Owlet has unveiled its Owlet360 subscription in the United Kingdom and Ireland. This service provides parents with personalized data on their infants' sleep and health patterns, maintaining key features such as live vital signs monitoring at no additional cost.
Expanding its international presence further, Owlet introduced the Dream Sock infant monitor to Australia and New Zealand markets. Approved by Australia’s Therapeutic Goods Administration, the Dream Sock tracks infant pulse rate, oxygen saturation, and sleep trends, reinforcing Owlet’s global product portfolio.
From an investment perspective, initial analyst coverage of Owlet reflects positive outlooks. TD Cowen recently initiated coverage with a Buy recommendation and elevated its price target to $19 from $15. Likewise, William Blair commenced coverage with an Outperform rating, citing strong growth potential within Owlet's pediatric health monitoring platform.
These advancements underpin Owlet’s strategic priorities aimed at enhancing product accessibility and expanding market penetration internationally, signifying the company’s commitment to broadening its consumer base and strengthening its competitive positioning in pediatric health technology.